EXPRESSION OF MALARIA MSP-1 P42 C-TERMINAL FRAGMENT

疟疾是一种热带寄生虫病， 多年来的健康威胁。 每年，大约有5亿 全世界有100万至200万人受到感染， 大多数病例发生在非洲。 在这个时候，有一个伟大的 我们需要控制这种疾病的传播。 疟疾的发展 疫苗已经集中在使用重组蛋白来克服 传统疫苗的局限性。 拟议研究的目标 是产生一种高免疫原性的重组亚单位， 来研制抗疟疾的疫苗 第一阶段研究将测试 利用真核细胞系统表达和分泌的可行性 重组裂殖子表面蛋白亚基p42，其具有天然- 就像确认。先前表达p42亚基的尝试导致 低水平的表达。 为此提出的表达系统 研究已经表明表达高水平的重组蛋白。 使用该系统表达疟疾蛋白质可能有助于 开发安全、有效和具有成本效益的疫苗。 建议的商业应用 疟疾对健康构成重大威胁。 每年约500 100万人感染，1 - 2百万人死亡。 目前 没有疟疾疫苗。 该研究将表达和 研制疫苗的疟疾亚单位。 成功 高水平表达该亚基可能有助于 开发安全、有效和具有成本效益的疟疾疫苗。

Malaria is a tropical parasitic disease that has been a significant health threat over the years. Each year, approximately 500 million people become infected and 1 to 2 million die worldwide, with the majority of cases occurring in Africa. At this time, there is a great need to control the spread of this disease. The development of malaria vaccines has focused on the use of recombinant proteins to overcome the limitations of conventional vaccines. The goal of the proposed research is to produce a highly immunogenic recombinant subunit that can be used to formulate a vaccine against malaria. Phase I research will test the feasibility of utilizing a eukaryotic cell system to express and secrete a recombinant merozoite surface protein subunit, p42, that has a native- like confirmation. Previous attempts to express the p42 subunit resulted in low levels of expression. The expression system proposed for this research has been shown to express high levels of recombinant proteins. Use of this system for expression of malaria proteins could contribute to the development of a safe, efficacious and cost effective vaccine. PROPOSED COMMERCIAL APPLICATION Malaria poses a significant health threat. Annually, approximately 500 million people become nfected and 1 to 2 million die. Currently, there is no vaccine for malaria. The proposed research will express and secret a malaria subunit targeted for vaccine development. Successful expression of high levels of this subunit could contribute to the development of a safe, efficacious and cost effective malaria vaccine.